DBV Technologies (NASDAQ:DBVT) Share Price Crosses Above 50-Day Moving Average – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $20.69 and traded as high as $20.92. DBV Technologies shares last traded at $20.00, with a volume of 174,566 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Guggenheim reissued a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.25.

DBV Technologies Stock Down 1.8%

The company’s fifty day moving average is $20.69 and its two-hundred day moving average is $19.05. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -4.48 and a beta of -0.96.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million. Sell-side analysts predict that DBV Technologies S.A. will post -0.47 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MPM Bioimpact LLC purchased a new stake in DBV Technologies during the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Octagon Capital Advisors LP acquired a new stake in shares of DBV Technologies during the 2nd quarter worth about $9,315,000. New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies during the 3rd quarter worth about $34,000. Finally, Artisan Partners Limited Partnership purchased a new stake in DBV Technologies during the third quarter worth approximately $519,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.